AstraZeneca on ‘independent’ manufacturing; Samsung Bio’s next ADC deal

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

As­traZeneca CEO Pas­cal So­ri­ot said dur­ing its fourth-quar­ter earn­ings press event that, al­though the phar­ma gi­ant does not source “a lot” of its prod­ucts with Catal­ent, the re­cent­ly-an­nounced No­vo-Catal­ent deal re­in­forces its aim to be as self-suf­fi­cient as pos­si­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.